BRAF and non-small cell lung carcinoma: The inhibition of BRAF V600E and its downstream effector MEK with oral inhibitors (dabrafenib and trametinib, respectively) is the most effective strategy in terms of activity and efficacy in metastatic BRAF V600E NSCLC [105].